M&M shares might dip momentarily, but their medium-term outlook remains positive with robust performance in the auto sector.

CEO David Joyner highlighted the company's Q4 adjusted EPS of $1.19 and adjusted operating income of $2.7 billion. He introduced 2025 adjusted EPS guidance of $5.75 to $6.00, emphasizing recovery in ...

AEON Biopharma, Inc. (NYSE: AEON) (the "Company"), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a ...

While the 10% tariff on Chinese goods won’t have too much impact on branded drugs, generics are struggling to pivot.

Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary ...

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) – ...

The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.

Biocon plans to list its biosimilars business by March 2026 and aims for a double-digit market share in the U.S. for five new biosimilars launching next fiscal year. The U.S. market, already ...

The company is also awaiting approval for its biosimilar Denosumab, used to treat osteoroposis, after which the product will be launched. Biocon also has three products lined up for launch in Europe.

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the Zacks Consensus Estimate of 70 cents. Adjusted earnings declined 29% year over ...

Dr. Reddy's Lab is undervalued due to exaggerated concerns about Revlimid revenue decline and the underappreciated potential of new high-growth products like biosimilars and GLP-1 drugs.

Ozempic gains expanded approval; Boxed Warning added to MS treatment label; Monotherapy approval granted to Spravato; Leqembi gains maintenance regimen; Enhertu gains new breast cancer indication.